News - OxyDial Inc

Sep 18 2025

Fulcrum Therapeutics Showcases Promising Posiradir Data, Bolstering Confidence in a New Sickle Cell Disease Paradigm

Fulcrum Therapeutics presented compelling Phase 1B data for its lead candidate, Posiradir, at the H.C. Wainwright Conference, underscoring its potential as a novel oral treatment for sickle cell disease (SCD). …

OxyDial

Sep 10 2025

Sanofi’s Wayrilz Secures FDA Approval, Pioneering a New BTK Era in Immune Thrombocytopenia

Sanofi has achieved a significant milestone with the FDA approval of Wayrilz (rilzabrutinib) for immune thrombocytopenia (ITP), marking it as the first Bruton’s tyrosine kinase (BTK) inhibitor approved for this …

OxyDial

Sep 5 2025

Oryzon Cleared to Start Phase 1b Trial of Sickle Cell Drug Iadademstat in Europe

Oryzon Genomics SA has received approval from the European Medicines Agency to initiate its Phase 1b RESTORE trial for iadademstat in patients with sickle cell disease (SCD). The trial will …

OxyDial

Aug 27 2025

AstraZeneca Finalizes Acquisition of FibroGen China, Strengthening Roxadustat’s Position in Key Market

AstraZeneca has cleared a major hurdle with China’s approval of its $160 million acquisition of FibroGen, Inc.’s China unit. This strategic move grants AstraZeneca full regional rights to the anemia …

OxyDial

Aug 21 2025

Roxadustat Gains FDA Clearance for Phase 3 Trial in Lower-Risk MDS Anemia

FibroGen, Inc. and Astellas Pharma have reached a milestone with the FDA’s green light to advance roxadustat into Phase 3 trials for anemia in lower-risk myelodysplastic syndromes (LR-MDS). This oral …

OxyDial

Aug 14 2025

Agios Pharmaceuticals Achieves Landmark Approval for PYRUKYND® in Thalassemia in Saudi Arabia

Agios Pharmaceuticals has made history with the first-ever regulatory approval of PYRUKYND® (mitapivat) for thalassemia, granted by Saudi Arabia’s SFDA – هيئة الغذاء والدواء under its Breakthrough Medicines Program. This …

OxyDial

Aug 7 2025

Novo Nordisk Partners With ASH to Strengthen Sickle Cell Disease Care Across Sub-Saharan Africa

NovoNordisk has launched a strategic three-year partnership with the American Society of Hematology (@ASHSociety) to enhance sickle cell disease (SCD) care in sub-Saharan Africa. The collaboration will strengthen the Consortium …

OxyDial

Jul 31 2025

Functional Fluidics Collaborates With Safi Biotherapeutics to Advance Manufactured Red Blood Cells for Sickle Cell Disease

Functional Fluidics has partnered with Safi Biotherapeutics Inc to validate the quality and efficacy of Safi’s stem-cell-derived manufactured red blood cells (mRBCs) for sickle cell disease (SCD). This collaboration aims …

OxyDial

Jul 24 2025

Pfizer’s Inclacumab Study Advances as a Potential Breakthrough for Sickle Cell Disease

Pfizer has shared an update on its open-label extension study evaluating the long-term safety of inclacumab in individuals with sickle cell disease (SCD). This monoclonal antibody, administered intravenously every 12 …